<DOC>
	<DOCNO>NCT01950364</DOCNO>
	<brief_summary>This open-label trial estimate concentration brentuximab vedotin relapsed/refractory Hodgkin lymphoma ( HL ) relapsed/refractory systemic anaplastic large cell lymphoma ( sALCL ) participant treat either brentuximab vedotin brentuximab vedotin + rifampicin .</brief_summary>
	<brief_title>A Phase 1 Study Patients With Relapsed Refractory Hodgkin Lymphoma Systemic Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Male female participant 18 year 75 year old , relapsed refractory HL relapse refractory sALCL previously receive least 1 multiagent chemotherapy Measurable disease An Eastern Cooperative Oncology Group ( ECOG ) performance 0 1 Female participant postmenopausal least 1 year screen visit , surgically sterile , agree practice 2 effective method contraception , time , time signing informed consent form 30 day last dose study drug , agree practice true abstinence Male participant agree practice effective barrier contraception entire study treatment period 6 month last dose study drug agree practice true abstinence Clinical laboratory value specify study protocol Participants rifampicin contraindicate Previously receive allogeneic transplant . Participants current diagnosis primary cutaneous anaplastic large cell lymphoma ( ALCL ) ( participant whose ALCL transform sALCL eligible ) . Known cerebral/meningeal disease include sign symptom progressive multifocal leukoencephalopathy ( PML ) Female participant lactate breastfeeding pregnant Known human immunodeficiency virus ( HIV ) positive , Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin</keyword>
	<keyword>Anaplastic Large-cell</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>